ライフサイエンスコーパス: BDI

1 BDI scores >/=10 were reported in four of the 72 women (

2 BDI scores, however, significantly predicted increased m

3 (BDI)Zn-1 also enables controlled copolymerization of OCA

4 [(BDI-1)ZnO(i)()Pr](2) polymerized (S,S)-lactide to isotac

5 [(BDI-1)ZnO(i)Pr](2) [(BDI-1) = 2-((2,6-diisopropylphenyl)

6 (BDI-2)ZnN(SiMe(3))(2) inserts CO(2) and eliminates trime

7 [(BDI-2)ZnOMe](2) [(BDI-2) = 2-((2,6-diethylphenyl)amido)-

8 [(BDI-7)Zn(mu-OAc)](2) [(BDI-7) = 3-cyano-2-((2,6-diethylp

9 of (BDI-IE)Zn(OCH(CH3 )COOCH3 ) ((BDI)Zn-1, (BDI-IE)=2-((2,6-diethylphenyl)amino)-4-((2,6-diisopropyl

10 t)Bu)](2)(mu-RC(6)H(5))][B(C(6)F(5))(4)](2) (BDI(#) = (ArNC(Me))(2)CH(2)).

11 [(BDI-7)Zn(mu-OAc)](2) [(BDI-7) = 3-cyano-2-((2,6-diethylphenyl)amido)-4-((2,6-di

12 [(BDI-1)ZnO(i)Pr](2) [(BDI-1) = 2-((2,6-diisopropylphenyl)amido)-4-((2,6-diisop

13 [(BDI-2)ZnOMe](2) [(BDI-2) = 2-((2,6-diethylphenyl)amido)-4-((2,6-diethylphe

14 A total of 200 BDI patients [age 54(20-83); 64 male], followed up for m

15 Test (RAVLT), Beck Depression Inventory-21 (BDI-21), and World Health Organization Quality of life-B

16 ated cationic inverted sandwich complex 8 [[(BDI(#))Nb(N(t)Bu)][(BDI)Nb(N(t)Bu)](mu-C(6)H(5))][B(C(6)

17 e deterioration (increase >/=8 HAM-D or >/=9 BDI points), extreme nonresponse (posttreatment HAM-D sc

18 (6)F(5))(4)] and the dicationic complex 9 [[(BDI(#))Nb(N(t)Bu)](2)(mu-RC(6)H(5))][B(C(6)F(5))(4)](2)

19 larger proportion of remissions defined as a BDI-II score </=8 (68.3% compared with 44.5%) compared w

20 prospective database of all patients with a BDI following LC was maintained.

21 in one-pot reactions utilizing a Lewis acid BDI(CF3)-Zn-N(SiMe3)2 (1) catalyst.

22 Immediate and early repair after BDI results in comparable, if not better long-term outco

23 lectronic structure in a series of (BDI)Al, (BDI)AlX2, and (BDI)AlR2 coordination compounds (X = F, C

24 The monocation and dication analogues {[(BDI)(N(t)Bu)Nb]2(mu-eta(3):eta(3)P4)}{B(Ar(F))4}n (5, n

25 sed on HRSD scores of 6 or lower (37.5%) and BDI scores of 9 or lower (43.8%) compared with women in

26 hypothesized that the combination of AA and BDI causes oxidative damage in vivo.

27 tion of high plasma concentrations of AA and BDI, or BDI alone, causes oxidative damage to lipids and

28 and mood assessments using the PRIME-MD and BDI instruments were performed at baseline, right after

29 ioxidant according to B-ALP, MPO, RANKL, and BDI values (P <0.05).

30 sion severity measured with the SIGH-SAD and BDI-II improved significantly and comparably with CBT-SA

31 4D Flow MRI based quantification of TVSS and BDI which are closely linked to blood damage.

32 of the form (BDI)ZnOR (R = alkyl, acyl) and (BDI)ZnN(SiMe3)2 are highly active catalysts for the alte

33 ons about the aluminum atoms in (BDI)Al and (BDI)AlH2 are similar relative to the (BDI)AlX2 and (BDI)

34 For (BDI)Al and (BDI)AlH2 the experimental Al K-edge XANES spectra and sp

35 2 are similar relative to the (BDI)AlX2 and (BDI)AlMe2 compounds, despite having different formal oxi

36 formally trivalent compounds (BDI)AlX2 and (BDI)AlR2.

37 ture in a series of (BDI)Al, (BDI)AlX2, and (BDI)AlR2 coordination compounds (X = F, Cl, I; R = H, Me

38 6-diisopropylphenyl)imino)-2-penten e)] and (BDI-2)ZnX [(BDI-2) = 2-((2,6-diethylphenyl)amido)-4-((2,

39 4-((2,6-diethylphenyl)imino)-2-pentene] and (BDI-1)ZnO(i)Pr [(BDI-1) = 2-((2,6-diisopropylphenyl)amid

40 (mu-OMe)(mu,eta(2)-O(2)COMe)Zn(BDI-2)] and [(BDI-1)Zn(mu,eta(2)-O(2)CO(i)Pr)](2), respectively.

41 ) at 50 degrees C using [(BDI-1)ZnOAc] and [(BDI-2)ZnOAc] show orders in [Zn](tot) of 1.73 +/- 0.06 a

42 r is first order in both monomer as well as (BDI-1)ZnO(i)()Pr concentration.

43 exercise rates were high (>80%), and average BDI scores were low.

44 A race by baseline BDI-II interaction was observed (P=0.003) in which eleva

45 ontrolling for baseline depression (baseline BDI HR: 1.1, 95% CI: 1.06 to 1.14, p < 0.001) and establ

46 y centre and minimised according to baseline BDI score, whether the general practice had a counsellor

47 mophore, a benzylidenedimethylimidazolinone (BDI) dye, is nearly nonfluorescent (Phif < 0.001) in com

48 here was no differential association between BDI-II change and outcomes in blacks versus whites.

49 o examine the etiological boundaries between BDI and BDII by assessing their familial aggregation/coa

50 Our results suggest a distinction between BDI and BDII in etiology, partly due to genetic differen

51 inhibitor encoding the double bromodomains (BDI/II) of Brd4 can competitively dissociate endogenous

52 ed sandwich complex 8 [[(BDI(#))Nb(N(t)Bu)][(BDI)Nb(N(t)Bu)](mu-C(6)H(5))][B(C(6)F(5))(4)] and the di

53 lf-report of depressive symptoms assessed by BDI-II score (range 0-63), analysed by intention to trea

54 11 of these were significantly depressed by BDI criteria.

55 tients with more breathlessness (measured by BDI and VAS for breathing) and more abnormal physiologic

56 romatin and that replacing Brd4 molecules by BDI/II causes abnormal nucleosome aggregation and chroma

57 ccording to kinetic studies, propagation by (BDI-1)ZnO(i)()Pr is first order in both monomer as well

58 However, when comparing BDI and BDII patients directly, we did not detect any si

59 6-Me2C6H3) yields the eta2-ketimine complex (BDI)(Me2C=NXyl)Nb(NCMe3), whose characterization and rea

60 beta-diketiminato dimethyl niobium complex (BDI)Me2Nb(NtBu) is shown to lead to a variety of product

61 niobium inverted arene sandwich complexes [[(BDI)Nb(N(t)Bu)](2)(mu-RC(6)H(5))] (7a: R = H and 7b: R =

62 om that of the formally trivalent compounds (BDI)AlX2 and (BDI)AlR2.

63 o-ethene-dechlorinating bacterial consortium BDI-SZ containing Dehalococcoides mccartyi (Dhc) strains

64 OR,1.63;95%CI,1.05-2.54;P = .03); continuous BDI-II score (OR, 1.19; 95%CI, 0.95-1.49; P = .14); GAD

65 In contrast, (BDI-2)ZnO(i)()Pr [(BDI-2) = 2-((2,6-diethylphenyl)amido)

66 rt the use of (BDI-IE)Zn(OCH(CH3 )COOCH3 ) ((BDI)Zn-1, (BDI-IE)=2-((2,6-diethylphenyl)amino)-4-((2,6-

67 he Cp ligand in the cation, [ORe(eta(5) -Cp)(BDI)](+) (3(+) ), which allows for nucleophilic attack b

68 pared with patients that were not depressed (BDI < 10; n = 96).

69 rimary outcome was recovery from depression (BDI score <10) at 4 months.

70 43 (38%) patients recovered from depression (BDI score <10) in the intervention group versus 23 (24%)

71 Measures of depression (BDI-II), anxiety (STAI-T) and trauma-related symptoms (T

72 A series of zinc beta-diiminate (BDI) complexes and their solid-state structures, solutio

73 The synthesis of 11 beta-diimine [(BDI)-H] ligands, with varying N-aryl substituents and br

74 um(III) and tantalum(III) beta-diketiminate (BDI) tert-butylimido complexes to produce the bridging c

75 tiation of ROP in comparison to the dimeric (BDI)Zn complex.

76 for 35 adolescents with bipolar I disorder (BDI) and 37 healthy adolescents.

77 ertainty remains whether bipolar I disorder (BDI) and bipolar II disorder (BDII) differ etiologically

78 Doxo/(BDI)ZnN(TMS)(2)-mediated LA polymerizations yielded Doxo

79 ydride (SA) to mimic the initiation of Doxo/(BDI)ZnN(TMS)(2)-mediated LA polymerization, Doxo-14-succ

80 known as nanoconjugates (NCs), through Doxo/(BDI)ZnN(TMS)(2)-mediated [(BDI) = 2-((2,6-diisopropylphe

81 When Doxo/(BDI)ZnN(TMS)(2) was mixed with 1-pyrenemethanol (Pyr-OH)

82 When Doxo/(BDI)ZnN(TMS)(2) was mixed with succinic anhydride (SA) t

83 he Beck Depression Inventory-Second Edition (BDI-II), remission status based on severity cutoff score

84 nd Beck Depression Inventory-Second Edition (BDI-II, administered before treatment, at week 3, and af

85 3),GAD(OR, 2.47; 95%CI, 1.23-4.97), elevated BDI-II (OR, 1.81; 95%CI, 1.20-2.73), elevated HADS-A sco

86 4%] had comorbidity);220(27.4%) had elevated BDI-II [Beck Depression Inventory II] scores (14), and 3

87 covariance showed nonsignificant effects for BDI and GAF scores.

88 (2.0% compared to 9.8% in the TAU group for BDI-II category change).

89 The heritabilities for BDI and BDII were estimated at 57% (95% CI 32%-79%) and

90 The heritability for BDI and BDII and the genetic correlation across psychiat

91 schizophrenia, showed different patterns for BDI and BDII.

92 between treatment trajectories over time for BDI and GDS.

93 For (BDI)Al and (BDI)AlH2 the experimental Al K-edge XANES sp

94 the higher transition energies observed for (BDI)AlX2 systems with more electronegative X(1-) ligands

95 s in [Zn](tot) ranging from 1.0 to 1.8 for [(BDI)ZnOAc] complexes.

96 Complexes of the form (BDI)ZnOR (R = alkyl, acyl) and (BDI)ZnN(SiMe3)2 are high

97 tion mechanism, where complexes of the form (BDI-1)ZnOCH(Me)CH(2)CO(2)R are the active species.

98 mino)-2-penten e] react with CO(2) to form [(BDI-2)Zn(mu-OMe)(mu,eta(2)-O(2)COMe)Zn(BDI-2)] and [(BDI

99 iminates trimethylsilyl isocyanate to give [(BDI-2)Zn(mu-OSiMe(3))](2).

100 y entry was 8, with 28% of the sample having BDI-II scores of 14 or higher.

101 mptoms of depression, as indicated by higher BDI scores over a 1-year interval (1-point BDI change ha

102 However, (BDI)Al was unique in that it exhibited a low-energy feat

103 e outpatients with a diagnosis of BD type I (BDI) or BD type II (BDII), predominantly in a depressed

104 ssion with the Beck Depression Inventory II (BDI-II) and psychiatric interview (Diagnostic and Statis

105 completed the Beck Depression Inventory II (BDI-II) score were randomized (1:1) between April 2003 a

106 ire (CSQ), the Beck Depression Inventory II (BDI-II), and the McGill Pain Questionnaire.

107 tests and the Beck Depression Inventory II (BDI-II).

108 everity on the Beck Depression Inventory-II (BDI-II) and remission on the PHQ-9.

109 scores on the Beck Depression Inventory-II (BDI-II) and the Beck Scale for Suicidal Ideation (BSSI).

110 ssessed by the Beck Depression Inventory-II (BDI-II) at baseline and after 3 months with all-cause mo

111 f-administered Beck Depression Inventory-II (BDI-II), National Eye Institute Visual Function Question

112 y employed the Beck Depression Inventory-II (BDI-II), the Hospital Anxiety and Depression Scale (HADS

113 ated (CGI) and Beck Depression Inventory-II (BDI-II).

114 However, EPO improved BDI (P=0.02) and WHOQOL-BREF (P=0.01), and this was main

115 -0.42) and -3.65 (95% CI, -6.18 to -1.12) in BDI-II scores in favor of CBT vs TAU and TC, respectivel

116 opmental abnormalities during adolescence in BDI in anterior cortices, including altered developmenta

117 follow-up BDI score (p > 0.10) or change in BDI score between baseline and follow-up (p > 0.10).

118 eived EUC alone (adjusted mean difference in BDI-II score = -4.45; 95% CI -7.26, -1.63; p = 0.002) an

119 In blacks, an increase in BDI-II score from baseline to 3 months was associated wi

120 11; P = .91) or response (> 50% reduction in BDI-II from baseline: placebo, 49.0% vs omega-3, 47.7%;

121 of participants achieving a 50% reduction in BDI-II in the GSH-CBT arm.

122 aintained at levels similar to those seen in BDI control rats.

123 e distributions about the aluminum atoms in (BDI)Al and (BDI)AlH2 are similar relative to the (BDI)Al

124 In bile duct-incannulated (BDI) rats, bile duct obstruction present for 7 days was

125 TVSS), which is used for blood damage index (BDI) estimation, was not severely affected by SNR and vo

126 resses and corresponding blood damage index (BDI) in stenotic turbulent blood flow.

127 ppa B ligand (RANKL) and bone density index (BDI) were determined stereologically in the bone section

128 thlessness, Mahler's baseline dyspnea index (BDI) and a visual analog scale (VAS) for breathing, were

129 bility to prevent it (bronchodilation index [BDI] versus bronchoprotection index [BPI]: 1.62 +/- 0.21

130 An exploratory comparison of individual BDI-II items indicated that the Met allele was associate

131 one (BVL) using the zinc alkoxide initiator (BDI-1)ZnO(i)()Pr [(BDI-1) = 2-((2,6-diisopropylphenyl)am

132 A majority of bile duct injuries (BDI) sustained during laparoscopic cholecystectomy requi

133 n the incidence of major bile duct injuries (BDI).

134 -and-death (BD), birth-death-and-innovation (BDI), equal rates (ER), symmetric (SYM), general time-re

135 s with depression (Beck Depression Inventory BDI-II score >/= 20) were recruited from 27 primary care

136 14 or more on the Beck depression inventory (BDI) and a confirmed diagnosis of depression were recrui

137 easured using the Beck depression inventory (BDI) and a daily rating scale measuring the severity of

138 nts completed the Beck Depression Inventory (BDI) at ages 61.5 years (time 1) and 63.4 years (time 2)

139 ymptoms using the Beck Depression Inventory (BDI) at baseline and again 1 year later.

140 who completed the Beck Depression Inventory (BDI) at baseline and were followed over 5.9 years.

141 ssessed using the Beck Depression Inventory (BDI) during hospitalization and at 1 and 3 months after

142 pression with the Beck Depression Inventory (BDI) scale in 291 patients with CHF hospitalized as a re

143 nnaire (FIQ), the Beck Depression Inventory (BDI) scale, and visual analog scales (VAS) for global we

144 as indicated by a Beck Depression Inventory (BDI) score > or = 10 (n = 47) showed attenuated FMD (p =

145 The Beck Depression Inventory (BDI) scores of women who received IPT declined from 23.6

146 The Beck Depression Inventory (BDI) was administered to 11 patients with MS and 22 heal

147 sion (Ham-D), the Beck depression inventory (BDI), and adverse events.

148 Form 36 (SF-36), Beck Depression Inventory (BDI), and one additional suicide question.

149 t Form-36 and the Beck Depression Inventory (BDI), as well as suicide items from the Symptom Checklis

150 ures included the Beck Depression Inventory (BDI), Hamilton Rating Scale for Anxiety (HAM-A), the Glo

151 ionnaire, and the Beck Depression Inventory (BDI).

152 ssed by using the Beck Depression Inventory (BDI).

153 le (HAM-D) and/or Beck Depression Inventory (BDI).

154 ssion (HAM-D) and Beck Depression Inventory (BDI).

155 n Scale (GDS) and Beck Depression Inventory (BDI; defined as a 50% reduction in symptoms from baselin

156 ressive symptoms (Beck Depression Inventory [BDI-II] score >/=14 and met ICD-10 depression criteria).

157 s for >/=6 weeks, Beck depression inventory [BDI] score >/=14 and international classification of dis

158 [QIDS-SR] or the Beck Depression Inventory [BDI]), obtained for up to 1 week after ketamine administ

159 lly redox-active, bleomycin-detectable iron (BDI) in their plasma.

160 years, 200 patients were treated for a major BDI following LC.

161 tin(II) isopropyl-(S)-lactate complex, ((Me)BDI(DIPP))SnOCH(Me)COO(i)Pr (14), has been synthesized a

162 the propagating species by treatment of ((Me)BDI(DIPP))Sn(NMe(2)) with isopropyl-(S)-lactate.

163 )Bu)(R-C(6)H(5))] (2a: R = H and 2b: R = Me, BDI = N,N'-diisopropylbenzene-beta-diketiminate) were sy

164 dination compounds (X = F, Cl, I; R = H, Me; BDI = 2,6-diisopropylphenyl-beta-diketiminate).

165 Mean BDI scores or odds for having mild to severe BDI scores,

166 Mean BDI-II scores were lower in the GSH-CBT group at 4 month

167 .5-51.1]), the intervention group had a mean BDI-II score of 19.2 (SD 13.8) compared with a mean BDI-

168 score of 19.2 (SD 13.8) compared with a mean BDI-II score of 23.4 (SD 13.2) for the usual care group

169 h the 12-month follow-up (difference in mean BDI-II score between 3 and 12 months = -0.34; 95% CI -2.

170 are, aerobic exercise resulted in lower mean BDI-II scores at 3 months (aerobic exercise, 8.95; 95% C

171 ot stressful events in midlife, and the mean BDI score (average of time 1 and time 2) or mild to seve

172 y (Trait-A) were identical at 33.5; the mean BDI score was 8.7+/-7.6.

173 The median BDI-II score at study entry was 8, with 28% of the sampl

174 s), through Doxo/(BDI)ZnN(TMS)(2)-mediated [(BDI) = 2-((2,6-diisopropylphenyl)amido)-4-((2,6-diisopro

175 luences the ROP of OCAs, with the monomeric (BDI)Zn-1 possessing superior catalytic activity for the

176 Monometallic niobium arene complexes [Nb(BDI)(N(t)Bu)(R-C(6)H(5))] (2a: R = H and 2b: R = Me, BDI

177 When the steric bulk of BDI was reduced or when the BDI ligand was removed, sign

178 Incubation of BDI-containing plasma from preterm infants did not resul

179 ce reporting the perioperative management of BDI following LC.

180 ts regarding the perioperative management of BDI.

181 pared with the general population, the OR of BDI was 17.0 (95% confidence interval [CI] 13.1-22.0) in

182 en comparing the 75th and 25th percentile of BDI-II (score of 15 and 5, respectively).

183 [CI] 13.1-22.0) in first-degree relatives of BDI patients, higher than that of BDII patients (OR 9.8,

184 ts and 9.8 (95% CI 7.7-12.4) in relatives of BDI patients.

185 s) were used to measure the relative risk of BDI and BDII in relatives of individuals diagnosed with

186 The push-pull substitution of BDI also leads to sensitive fluorescence-quenching respo

187 The mean interval from the time of BDI to referral was 29.1 weeks (median 3 weeks).

188 natively synthesized upon hydrogenolysis of (BDI)Nb(N(t)Bu)Me2 in the presence of P4.

189 itiator to polymerize LA in the presence of (BDI)ZnN(TMS)(2), the polymerization was complete within

190 Furthermore, the reaction of (BDI)Me2Nb(NCMe3) with XylNC (Xyl = 2,6-Me2C6H3) yields t

191 o probe electronic structure in a series of (BDI)Al, (BDI)AlX2, and (BDI)AlR2 coordination compounds

192 The use of (BDI)MgN(TMS)(2) in such a reaction also resulted in redu

193 Herein, we report the use of (BDI-IE)Zn(OCH(CH3 )COOCH3 ) ((BDI)Zn-1, (BDI-IE)=2-((2,6

194 response (posttreatment HAM-D score >/=21 or BDI score >/=31), superior improvement (HAM-D or BDI dec

195 high plasma concentrations of AA and BDI, or BDI alone, causes oxidative damage to lipids and protein

196 t had at least a 50% improvement in Ham-D or BDI at week 12 compared with the placebo group; patients

197 score >/=31), superior improvement (HAM-D or BDI decrease >/=95%), and superior response (posttreatme

198 ferences between CBT and ADM on the HAM-D or BDI or in response or remission.

199 of any deterioration (increase >/=1 HAM-D or BDI point), reliable deterioration (increase >/=8 HAM-D

200 nd superior response (posttreatment HAM-D or BDI score of 0) using multilevel models.

201 of the oxo Re(V) beta-diketiminate, OReCl2 (BDI), with various cyclopentadienide (Cp) sources has be

202 ient fashion: 15% of non-depressed patients (BDI score 0 to 4), 29% of mildly depressed patients (BDI

203 e 0 to 4), 29% of mildly depressed patients (BDI score 10 to 16), and 37% of patients with moderately

204 when excess iron was added to adult plasma, BDI became detectable, and endogenous AA was rapidly oxi

205 r BDI scores over a 1-year interval (1-point BDI change hazard ratio [HR]: 1.07, 95% confidence inter

206 3 to 0.36; t(112) = 0.11; P = .91), pre-post BDI-II scores (placebo, 14.8 vs omega-3, 16.1; 95% diffe

207 zinc alkoxide initiator (BDI-1)ZnO(i)()Pr [(BDI-1) = 2-((2,6-diisopropylphenyl)amido)-4-((2,6-diisop

208 In contrast, (BDI-2)ZnO(i)()Pr [(BDI-2) = 2-((2,6-diethylphenyl)amido)-4-((2,6-diethylphe

209 enyl)imino)-2-pentene] and (BDI-1)ZnO(i)Pr [(BDI-1) = 2-((2,6-diisopropylphenyl)amido)-4-((2,6-diisop

210 The trinuclear side product {[(BDI)NbN(t)Bu]3(mu-P12)} (3) is also identified.

211 edefined indicators of depression remission (BDI-II < or = 8: placebo, 27.4% vs omega-3, 28.3%; odds

212 occupied molecular orbital on electron-rich (BDI)Al distinguishes its valence electronic structure fr

213 rage of time 1 and time 2) or mild to severe BDI scores (10-63 points at time 1 and time 2), or both,

214 BDI scores or odds for having mild to severe BDI scores, or both, increased according to number of mi

215 e the bridging cyclo-P4 phosphide species {[(BDI)(N(t)Bu)M]2(mu-eta(3):eta(3)P4)} (1, M = Nb; 2, M =

216 ronchoprotection was significantly stronger (BDI versus BPI: 3.40 +/- 0.43 versus 6.98 +/- 1.42, p =

217 he tau torsion of the meta-amino-substituted BDI systems leads to a zwitterionic twisted intermediate

218 .63; P = .02); elevated depression symptoms (BDI-II score 14)(OR,1.63;95%CI,1.05-2.54;P = .03); conti

219 n, having both elevated depressive symptoms (BDI > or =10) and a previous diagnosis of depression req

220 moderately-to-severely depressive symptoms (BDI score >16) took aspirin less than 80% of the time (p

221 least 50% reduction in depressive symptoms (BDI score) at 6 months compared with baseline.

222 subtype (BD type I or type II) revealed that BDI patients had significantly larger lateral ventricles

223 iable temperature NMR experiments show that (BDI-1)ZnO(i)()Pr is monomeric in benzene-d(6) solution.

224 The square sum of TVSS and the BDI at SNR >20 were underestimated by less than 1% and 1

225 The SF-36 complements the BDI and VAS scores for breathing in scleroderma lung dis

226 nonsignificant, improvement occurred in the BDI scale, the physician global VAS, and the VAS for fat

227 ces indicated that as the BPI increased, the BDI reached a plateau.

228 hile many efforts have been devoted into the BDI chromophore engineering for fluorescence recovery, l

229 t the phosphide ring but rather involves the BDI ligand to yield {[(BDI(#))Nb(N(t)Bu)]2(mu-eta(3):eta

230 S scores (F4,8.9=20.3; P<0.001), and not the BDI-II or HADS.

231 ADRS, the HAM-D, and the QIDS-SR but not the BDI.

232 However, protonation of the BDI ligands occurred readily on treatment with [H(OEt(2)

233 ression and on the cognitive subscale of the BDI-II.

234 ; P = .03) and a nonsignificant trend on the BDI (beta = -1.14; P = .08, statistical test for trend),

235 with clinically significant symptoms on the BDI and SF-36 Mental Health Scale were cases on the SCL-

236 Scores on the BDI and VAS for breathing were highly correlated (r = -0

237 Depression was defined as a score on the BDI of > or =10.

238 ), and continuous standardized scores on the BDI-II (OR, 1.31; 95% CI, 1.05-1.62) and the HADS-A (OR,

239 alization due to any cause and scores on the BDI-II at months 3 and 12.

240 of 0.4 points (95% CI, 0.01 to 0.72) on the BDI-II per therapy session was observed.

241 nificant treatment effects were found on the BDI-II.

242 H-SAD (47.6% and 47.2%, respectively) or the BDI-II (56.0% and 63.6%).

243 particle-hole symmetry characteristic to the BDI symmetry class stems from the distinct behaviour of

244 opological mechanical systems related to the BDI symmetry class.

245 Similar results were seen using the BDI.

246 e steric bulk of BDI was reduced or when the BDI ligand was removed, significant amounts of Doxo-4',1

247 olume ratio was strongly correlated with the BDI score in patients with MS (r = .86, p = .006).

248 scale was significantly correlated with the BDI-II (r = 0.67, P < 0.001), indicating its potential f

249 9% screened positive for depression with the BDI-II.

250 at is localized on Al and orthogonal to the (BDI)Al plane.

251 l and (BDI)AlH2 are similar relative to the (BDI)AlX2 and (BDI)AlMe2 compounds, despite having differ

252 One hundred eighty-eight sustained their BDI at an outside hospital.

253 Response according to BDI also did not differ significantly (telemedicine 19 [

254 BMI was unrelated to BDI-II, STAI-T, TSC-40, or TFEQ scores.

255 These ligands are converted to (BDI)ZnX complexes (X = OAc, Et, N(SiMe3)2, Br, Cl, OH, O

256 tween baseline exercise and either follow-up BDI score (p > 0.10) or change in BDI score between base

257 e correlations between [(18)F]PBR111 uptake, BDI scores, and hippocampal functional connectivities in

258 e) and 300 psi CO(2) at 50 degrees C using [(BDI-1)ZnOAc] and [(BDI-2)ZnOAc] show orders in [Zn](tot)

259 acid transport activity compared with 1-week BDI control rats.

260 There were no differences in weekly BDI-II scores (treatment x time interaction = 0.02; 95%

261 ive to healthy adolescents, adolescents with BDI showed greater volume contraction over time in a reg

262 ly with each other (r=0.85; P<0.01) and with BDI score (State-A, r=0.52; Trait-A, r=0.59; P<0.01).

263 frontal and parietal regions correlated with BDI scores and [(18)F]PBR111 distribution volume ratio.

264 ntibodies were significantly correlated with BDI scores; patients with BDI-II scores of > or =14 had

265 I in relatives of individuals diagnosed with BDI (n = 4309) and BDII (n = 4178).

266 ere not different between those infants with BDI (138 +/- 51 pg/ml, n = 19) and those without (126 +/

267 ly correlated with BDI scores; patients with BDI-II scores of > or =14 had higher serum levels of ant

268 ons of cyclohexene oxide (CHO) and CO2 with (BDI-1)ZnX [(BDI-1) = 2-((2,6-diisopropylphenyl)amido)-4-

269 Polymerization experiments with [(BDI-1)MgO(i)Pr](2) revealed that this complex is extreme

270 Kinetic studies with [(BDI-1)ZnO(i)Pr](2) indicate that the polymerizations are

271 n e] reacts with 1.0 equiv of CHO to yield [(BDI-7)Zn(mu,eta(2)-OAc)(mu,eta(1)-OCyOAc)Zn(BDI-7)].

272 t rather involves the BDI ligand to yield {[(BDI(#))Nb(N(t)Bu)]2(mu-eta(3):eta(3)P4)}[B(C6F5)4]2 (4).

273 orm [(BDI-2)Zn(mu-OMe)(mu,eta(2)-O(2)COMe)Zn(BDI-2)] and [(BDI-1)Zn(mu,eta(2)-O(2)CO(i)Pr)](2), respe

274 (BDI-7)Zn(mu,eta(2)-OAc)(mu,eta(1)-OCyOAc)Zn(BDI-7)].

275 hexene oxide (CHO) and CO2 with (BDI-1)ZnX [(BDI-1) = 2-((2,6-diisopropylphenyl)amido)-4-((2,6-diisop

276 lphenyl)imino)-2-penten e)] and (BDI-2)ZnX [(BDI-2) = 2-((2,6-diethylphenyl)amido)-4-((2,6-diethylphe